KLOW Peptide Blend (80mg)

Pre-blended GHK-Cu, BPC-157, TB-500 and KPV. Take the three peptides in GLOW (GHK-Cu, BPC-157 and TB-500) and add a fourth, KPV, and you have KLOW. The KPV fragment carries the anti-inflammatory end of alpha-MSH but none of its pigment-driving activity, so the blend moves away from being purely a skin-repair formula and toward wider recovery and inflammation work.

Recovery research: models spanning connective tissue, muscle and skin. Inflammation control: cytokine readouts and NF-κB activity. Gut-barrier research: kPV applied to intestinal epithelium models. No published trial has studied the four together as a finished product, so the evidence base is whatever sits on each individual compound's page. KPV's track record in gut-inflammation research is usually why investigators reach for KLOW in gastrointestinal and systemic inflammation models.

There is no single-product trial; you have to read the evidence on each component's own page, and it is KPV's colitis data that tends to make KLOW the pick for gut and inflammation designs.

There is no combined dataset, so each of the four components' own safety profiles are what apply.

In the published KLOW Peptide Blend research, the amounts used were 1 × 10⁻⁹ mol/L in ghk-cu: cell culture, human dermal fibroblasts (Pollard JD et al. (2005)); 200 or 2 μg/kg intraperitoneal, Once, 10 min after injury in bpc-157: rat, spinal cord injury (Perovic D et al. (2019)); 10 mg IV (day 1), 20 mg IV (day 2), each in 250 cc saline over 1 h, Once daily on 2 days in bpc-157: human safety pilot (Lee E et al. (2025)). These are the figures each study reports for its own model, listed in full in the dosage table on this page with links to PubMed. Peptide Aus supplies KLOW Peptide Blend for in-vitro research and does not give dosing guidance for people.

GLOW runs the same three peptides but leaves out KPV; KLOW folds in that NF-kB suppression for inflammation research.

Where the Wolverine stack is just BPC-157 and TB-500, KLOW brings GHK-Cu and KPV on top.

KLOW carries one additional peptide (KPV) and comes in a bigger 80mg vial. Beyond that it is the identical trio of compounds held at the identical ratio.

Add about 3 mL of bacteriostatic water slowly down the inside of the vial and swirl gently; do not shake. 80mg in 3 mL gives 26.7 mg/mL. Refrigerate at 2–8 °C after reconstitution and use within 8–12 weeks. The calculator has this vial preset.

Lyophilised: −20 °C, sealed, away from light and moisture. Reconstituted: 2–8 °C, used within 8–12 weeks, never frozen.

The Therapeutic Goods Administration (TGA) has not registered KLOW Peptide Blend as a medicine in Australia, and it carries no approval for use in humans or animals. What Peptide Aus sells is a research reagent intended for in-vitro laboratory work and nothing more. In Australia, supplying any substance for human use falls under the Therapeutic Goods Act and the Poisons Standard, and it is the purchaser who must ensure the material is used within the law. Anyone seeking treatment should consult a doctor.

Directly from Peptide Aus, from Australian stock: KLOW Peptide Blend (80mg) is $199.99 AUD including GST. Paid orders before 2pm AEST/AEDT dispatch the same business day, tracked.